Shots:

• The P-IIIb ALPINE Study involves assessing of Aristada and Invega Sustenna in 200 patients experiencing an acute exacerbation of schizophrenia- followed by an outpatient phase for a total of six months
• P-III study results: @4wks. reductions in Positive and Negative Syndrome Scale (PANSS) total scores (-17.4 points- -20.1 points); @9 & 25 wks. PANSS total scores continued to improve (-19.8 points- -22.5 points & -23.3 points- -21.7 points)
• Aristada is an injectable antipsychotic available as four doses (441 mg- 662 mg or 882 mg monthly- 882 mg q6w and 1064 mg once every two months) developed for Schizophrenia approved in the US

Ref: Alkermes | Image: American Pharma News